S
Scott Wadler
Researcher at New York University
Publications - 17
Citations - 619
Scott Wadler is an academic researcher from New York University. The author has contributed to research in topics: Chemotherapy & Doxorubicin. The author has an hindex of 13, co-authored 17 publications receiving 613 citations.
Papers
More filters
Long-term Swallowing Problems After Organ Preservation Therapy With Concomitant Radiation Therapy and Intravenous Hydroxyurea
TL;DR: Prolonged and debilitating functional swallowing abnormalities may occur after this aggressive concomitant chemotherapy and radiotherapy regimen.
Journal ArticleDOI
Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose Doxorubicin
Howard S. Hochster,Leonard Liebes,Scott Wadler,Ruth Oratz,J C Wernz,M Meyers,Michael F. Green,Ronald H. Blum,James L. Speyer +8 more
TL;DR: Myelotoxicity was dose limiting for ADR-529 at 600-750 mg/m2 when given with a fixed dose of doxorubicin at 60 mg/ m2 when used in combination; therefore, other mechanisms of cardioprotection must be involved.
Journal ArticleDOI
Krukenberg tumors: can management be improved?
Frances McGill,Diane B. Ritter,Caroline S. Rickard,Ronald N. Kaleya,Scott Wadler,Wilma Markus Greston,Katherine A. O'Hanlan +6 more
TL;DR: Krukenberg tumors were more common in premenopausal women with gastric or colon cancer compared to post menopausal women and should be considered at the time of GI cancer surgery, and requires further study.
Journal ArticleDOI
Adjuvant effects of lithium chloride on human mononuclear cells in suppressor-enriched and suppressor-depleted systems
TL;DR: Lithium may be enhancing thymidine uptake in response to mitogen at least in part by abrogating suppressor cell activity, and the observed increase inThymidine incorporation in the suppressor-depleted cultures suggests that lithium may also have a direct stimulatory effect on helper cell activity.
Journal ArticleDOI
Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea.
TL;DR: Octreotide acetate can be safely administered for the treatment of fluoropyrimidine-induced diarrhea in patients with gastrointestinal malignancies and there was a significant correlation between complete response to therapy and octreotide dose.